La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Indie Semiconductor a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Indie Semiconductor..

Indie Semiconductor (NASDAQ:INDI) Azioni, Catena delle Opzioni

Indie Semiconductor

Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for advanced Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the advanced user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.

indie Semiconductor, Inc. - Class A Common Stock

Indie Semiconductor Inc

Indie Semiconductor Inc Warrants (10/06/2026)

INDIA CAPITAL GROWTH FD by India Capital Growth Fund Ltd.

INDIE RANCH MEDIA INC by Indie Ranch Media, Inc.

INDIA CEMENT S/GDR 144A by India Cement Ltd.

India Cements Ltd

India Fund Inc

Indiana Resources Ltd

Indico Resources Ltd

INDIGENOUS BLOOM HEMP CRP by INDIGENOUS BLOOM HEMP CORP

Indigenous Bloom Hemp Corp

Indigo Books & Music Inc

INDIGO EXPL INC by Indigo Exploration, Inc.

Indigo Exploration Inc

Indiva Ltd

Indivior PLC

Indivior PLC ADR

Indivior PLC Ordinary Share

INDIEPUB ENTMT INC by indiePub Entertainment, Inc.

indiePub Entertainment Inc

WIIM

LOGI

Logitech International shares are trading higher after JP Morgan raised its price target on the stock from $93 to $99.

The healthcare sector will be on watch Wednesday with a highly anticipated earnings report from Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a href="https://www.benzinga.com/earnings">before market open.</a> 
Earnings Estimates: Analysts expect Johnson &amp; Johnson to report fourth quarter revenue of $22.44 billion according to data <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012125&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company has beaten analyst estimates for revenue in two straight quarters and eight of the last 10 quarters overall.
Analysts expect the company to report fourth quarter earnings per share of $2.00, down from $2.29 in last year's fourth quarter. The company has beaten analyst estimates for earnings per share in 10 straight quarters.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/01/43105398/fda-approves-johnson-johnsons-treatment-as-first-monotherapy-for-treatment-resistant-depression">FDA Approves Johnson &amp; Johnson&#8217;s Treatment As First Monotherapy For Treatment-Resistant Depression</a>
Key Items to Watch: Johnson &amp; Johnson has received several price target cuts from analysts in the last two months.
Bank of America <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">maintained a Neutral rating </a>and lowered the price target from $166 to $160. Citi maintained a Buy rating and lowered the price target from $185 to $175.
Freedom Capital Markets Chief Global Strategist Jay Woods highlighted the importance of Johnson &amp; Johnson's earnings report for the health care sector.
"The health care sector has remained under pressure and those following it are hoping JNJ can help bring it back to life," Woods wrote in a weekly <a href="https://jaywoods.substack.com/">newsletter</a>.
Woods said analysts and investors will be looking for the company's sales of key oncology drugs Darzalex and Carvykti. The market strategist also said investors and analysts will be looking for commentary on the recent acquisition of Cellular Therapies and its impact on the bottom line.
In the third quarter, Darzalex sales were up 22.9% year-over-year to $3.02 billion. Carvykti sales hit $286 million in the third quarter, up 87.6% year-over-year.
Woods highlighted the timing of the fourth-quarter results coming as shares have hit new 52-week lows recently.
"Johnson &amp; Johnson has dropped over -16% from its September peak making new 52-week lows as recently as last week. In fact, over the last 52 weeks, shares are lower by 8%."
With this being the company's fourth quarter, investors and analysts will also be looking for commentary on future guidance.
Johnson &amp; Johnson is a member of the Dow Jones Industrial Average and one of several Dow Jones stocks reporting financial results this week, putting ETFs like the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) into focus. 
JNJ Price Action: Johnson &amp; Johnson stock is up 1% to $148.43 on Tuesday versus a 52-week trading range of $140.68 to $168.85. The stock is down 9% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42747345/marjorie-taylor-green-went-christmas-shopping-for-stocks-heres-what-she-bought-before-holiday">Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here&#8217;s What She Bought Before Holiday</a></li>
</ul>
Photo: Shutterstock

Previews

Trading Ideas

SPDR Dow Jones Industrial Average ETF Trust

Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'?

On Tuesday, Guardant Health, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43094950/guardant-health-receives-medicare-coverage-for-guardant-reveal-on-smart-liquid-biopsy-platform-for" rel="noreferrer noopener">curative intent therapy</a>.
Guardant Reveal, which runs on Guardant&#8217;s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal residual disease (MRD). This test predicts cancer recurrence, helping to guide clinical decisions after surgery or chemotherapy.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41185292/fda-clears-exact-sciences-next-generation-colorectal-cancer-diagnostic-test" rel="noreferrer noopener">FDA Clears Exact Sciences&#8217; Next-Generation Colorectal Cancer Diagnostic Test</a>
As a result of this decision, the Guardant Reveal test is now covered for use in the CRC surveillance setting after curative intent treatment.
This represents an expansion from the prior Medicare coverage of Guardant Reveal testing for CRC only in the early post-surgical setting.
The tissue-free Guardant Reveal test uses a blood sample, in contrast to tumor-informed approaches to MRD testing, which require a healthcare provider to obtain a physical tissue specimen of the tumor.
William Blair, with an Outperform rating, sees this development as a strong <a href="https://www.benzinga.com/quote/GH/analyst-ratings" target="_blank" rel="noreferrer noopener">positive for the stock.</a>
Analyst Andrew Brackmann writes that the market reaction is justified, as reimbursement should enable the company to fully capitalize on its opportunities rather than limiting volumes to control cash burn, as it had previously.
Additionally, reimbursement and ongoing workflow improvements, which reduce costs, are expected to make Reveal gross margin positive later this year. The progress could help the company increase volumes (potentially exceeding the clinical volume growth target of 20%-plus for 2025), generate more revenue, and significantly reduce cash burn.
Price Action: GH stock is up 21.1% at $44.39 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43099267/why-digital-solutions-provider-supercoms-stock-is-rising-today" target="_blank" rel="noreferrer noopener">Why Digital Solutions Provider SuperCom&#8217;s Stock Is Rising Today</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

News

Health Care

Reiteration

Analyst Ratings

Movers

General

Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test

CF Industries shares are trading lower after Barclays downgraded the stock from Overweight to Equal-Weight while RBC Capital downgraded from Outperform to Sector Perform.

Agnico Eagle Mines shares are trading higher after Scotiabank maintained a Sector Outperform rating on the stock and raised its price target from $103 to $105.

United Airlines Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) will be reporting its fourth-quarter earnings on Tuesday. Wall Street expects $2.99 in EPS and $14.40 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=UAL" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 184.10% over the past year, 14.47% YTD.
Let&#8217;s look at what the charts indicate for United Airlines stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43074340/jim-cramers-market-outlook-strong-earnings-trump-inauguration-and-whats-next-for-investors">Jim Cramer&#8217;s Market Outlook: Strong Earnings, Trump Inauguration, and What&#8217;s Next for Investors</a>
<h2 class="wp-block-heading">UAL Stock Chart Strongly Bullish Ahead Of Q4 Earnings&nbsp;</h2>
UAL stock is displaying a strongly bullish trend, with its share price of $109.36 trading above the five, 20 and 50-day exponential moving averages. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21125516/Screenshot-2025-01-21-at-11.19.20-PM.png" alt="" class="wp-image-743256" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21125516/Screenshot-2025-01-21-at-11.19.20-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21125516/Screenshot-2025-01-21-at-11.19.20-PM-300x232.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012125&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
This indicates sustained buying pressure. The eight-day SMA (simple moving average) at $106.38, 20-day SMA at $101.57, and 50-day SMA at $97.15 all confirm a bullish setup, reinforcing momentum to the upside.
Additionally, UAL stock remains well above its 200-day SMA of $63.24, suggesting a long-term uptrend. The MACD (moving average convergence/divergence) indicator at 3.52 further signals bullish momentum, while the RSI (relative strength index) at 67.00 indicates strong buying interest but remains below overbought territory.
Overall, technical indicators support continued strength in UAL's price action.
<h2 class="wp-block-heading">United Airlines Analysts See 20% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/UAL/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on United Airlines stock stands at a Buy with a price target of $93.51. The latest analyst ratings from JP Morgan, Susquehanna and UBS suggest a $131 average price target, implying a 19.51% upside for United Airlines&#8217; stock.
Price Action: United Airlines stock was trading 2% higher at $109.59 at the time of publication Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/travel/25/01/42986606/us-global-investors-shines-in-2024-jets-etf-soars-33-amid-travel-boom-gold-shipping-funds-add-to-gains">US Global Investors Shines In 2024: JETS ETF Soars 33% Amid Travel Boom; Gold, Shipping Funds Add To Gains</a></li>
</ul>
Photo: Shutterstock

Earnings

Technicals

United Airlines Technical Signals Show Clear Skies Ahead Of Earnings

Scotiabank analyst Patrick Colville maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Sector Outperform and raises the price target from $205 to $225.

Price Target

Scotiabank Maintains Sector Outperform on Zscaler, Raises Price Target to $225

Corning shares are trading higher after Citigroup raised its price target on the stock from $55 to $58.

Scotiabank analyst Patrick Colville maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Sector Perform and raises the price target from $44 to $45.

TENB

Scotiabank Maintains Sector Perform on Tenable Holdings, Raises Price Target to $45

Morgan Stanley analyst Joseph Moore upgraded Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) to Overweight from Equal-Weight, raising <a target="_blank" href="https://www.benzinga.com/quote/QRVO/analyst-ratings" rel="noreferrer noopener">the price forecast to $106 from $90.</a>
Moore notes that he has seen value in Qorvo stock and attempted to capture it through upgrades, but the results have been only modest.
The analyst also highlighted challenges in the radio frequency space, particularly with pressure on the Chinese business, which increases concentration in other areas.
Per Moore, while the radio frequency market served by high-performance companies like Broadcom, Skyworks Solutions, and Qorvo will continue to grow, it will remain highly concentrated, primarily driven by high-end global phones.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43097512/apples-ai-advances-cant-offset-chinese-market-slowdown-says-analyst" rel="noreferrer noopener">Apple&#8217;s AI Advances Can&#8217;t Offset Chinese Market Slowdown, Says Analyst</a>
With the involvement of activist Starboard, the analyst views that Qorvo has the potential for a renewed earnings recovery.
According to Moore, Qorvo can achieve $9.63 in EPS by shifting from a &#8220;growth through diversification&#8221; strategy to focusing on its core radio frequency proficiency from calendar year 2026.
The analyst sees 48.0% gross margins and 25.8% operating margins by 2026, both aligned with their pre-covid average from 2015-2019.
The analyst suggests that Qorvo could accomplish this by reducing, but not eliminating, internal fab usage to stabilize gross margins through cycles, realigning operating expenses around the core radio frequency portfolio, and leveraging its discounted multiple for cash return to accelerate EPS growth.
While there is potential for top-line growth, especially with the Apple Inc. modem transition, the analyst emphasizes that the EPS growth forecast does not depend on aggressive revenue assumptions. Given Starboard&#8217;s track record and history with Qorvo, the analyst sees a significant opportunity to unlock value through a strategic course correction.
Price Action: QRVO shares are trading higher by 5.75% to $89.05&nbsp;at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/01/43088007/nvidia-apple-supplier-tsmc-halts-production-as-6-4-magnitude-earthquake-strikes-taiwan" target="_blank" rel="noreferrer noopener">Nvidia, Apple-Supplier TSMC Halts Production As 6.4 Magnitude Earthquake Strikes Taiwan</a></li>
</ul>

Upgrades

Markets

AAPL

AVGO

QRVO

Qorvo Could Achieve $9.63 EPS By 2026 With Activist Involvement, Morgan Stanley Upgrades Stock

Curtiss-Wright shares are trading higher after the company announced it received a $27 million contract to provide aircraft handling systems and support for the U.S. Navy. Also, Citigroup initiated coverage on the stock with a Buy rating and announced a price target of $410.

Scotiabank analyst Patrick Colville maintains SolarWinds (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) with a Sector Perform and raises the price target from $13 to $15.

Scotiabank Maintains Sector Perform on SolarWinds, Raises Price Target to $15

Wall Street saw a strong preference for small and mid-cap equities, with the Russell 2000 index leading the market as investors bet on more domestic-friendly policies following Donald Trump's inauguration on Jan. 20 as <a href="https://www.benzinga.com/topic/donald-trump">the 47th U.S. president.</a>
The Russell 2000 rallied 1.7%, while other large-cap indices trailed behind. The Dow Jones, composed of non-tech blue-chip companies, rose by 1.2%, while both the S&amp;P 500 and the Nasdaq 100 edged up 0.9%.
Most sectors traded higher, except for energy. The announcement of a national energy emergency raised concerns about a fossil fuel oversupply, sending oil prices down more than 2%. WTI crude dropped to $72.10 per barrel.
In the Treasury market, yields fell as investors appeared convinced by Trump's pledges on inflation control and lower federal spending. The 10-year Treasury yield declined by five basis points to 4.58%.
One of the session's most notable moves came from Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), which plunged 4.3%, marking its worst trading day since early August 2024. The decline followed a downgrade by Jefferies, citing challenges in iPhone sales in China.
In commodities, gold climbed 1.2% to a two-month high, aiming for its ninth gain in the past eleven sessions, supported by lower Treasury yields. In the crypto space, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rebounded 3% to $106,000 after briefly touching $100,000 overnight amid the absence of crypto-related remarks from Trump on his first day in office.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,314.89</td>
<td>1.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,995.44</td>
<td>1.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,053.00</td>
<td>0.9%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,630.38</td>
<td>0.9%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:20 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012125&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.9% to $602.64.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 1.1% to $439.55.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 0.8% higher to $525.61.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.8% to $229.50.</li>
<li>The&nbsp;Industrials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) outperformed, up 2%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.3%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
<ul>
<li>Charles Schwab Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) rallied 4.7%, eyeing the strongest session in over two months, after reporting stronger-than-expected quarterly results. </li>
<li>Other stocks reacting to earnings included Prologis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>), up 6.4%; 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>), up 5.5%; DR Horton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>), down 0.4%; KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>), down nearly 5% and Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>), up 0.4%.</li>
<li>General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) soared by nearly 6% after Deutsche Bank upgraded the stock from Hold to Buy, and raised the price target from $56 to $60.</li>
<li>Companies slated to report earnings after the close include Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), Interactive Brokers Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>), Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) and United Airlines Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/25/01/43103527/mexican-peso-canadian-dollar-slide-as-trump-threatens-25-tariffs-expert-eyes-price-hikes-on-typical-us-breakfast">Mexican Peso, Canadian Dollar Slide As Trump Threatens 25% Tariffs, Economist Eyes Price Hikes On &#8216;Typical US Breakfast&#8217;</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Commodities

Treasuries

Global

ETFs

$BTC

FITB

IBKR

NFLX

SCHW

Small Caps Soar, Apple Slips, Treasury Yields Fall On Trump Day 2: What's Driving Markets Tuesday?

Scotiabank analyst Patrick Colville maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Sector Perform and raises the price target from $39 to $42.

Scotiabank Maintains Sector Perform on Rapid7, Raises Price Target to $42

Scotiabank analyst Patrick Colville maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Sector Outperform and raises the price target from $200 to $225.

PANW

Scotiabank Maintains Sector Outperform on Palo Alto Networks, Raises Price Target to $225

Scotiabank analyst Patrick Colville maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Sector Perform and lowers the price target from $96 to $94.

OKTA

Scotiabank Maintains Sector Perform on Okta, Lowers Price Target to $94

Ratings for Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Corteva and provided 12-month price targets. The average target is $68.58, accompanied by a high estimate of $73.00 and a low estimate of $62.00. This current average has increased by 2.36% from the previous average price target of $67.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1737486060_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Corteva is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$73.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$68.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$69.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$67.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Corteva. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Corteva compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Corteva's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Corteva's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CTVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Corteva analyst ratings.</a>
<h2>Get to Know Corteva Better</h2>
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
<h3>Corteva: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Negative Revenue Trend: Examining Corteva's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -10.19% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Corteva's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -22.53%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.1%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Corteva's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.26%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.23.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTVA

12 Analysts Have This To Say About Corteva

ServiceNow shares are trading higher after JMP Securities raised its price target on the stock from $1000 to $1300.

Throughout the last three months, 12 analysts have evaluated Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Best Buy Co, presenting an average target of $102.5, a high estimate of $117.00, and a low estimate of $89.00. Highlighting a 5.02% decrease, the current average has fallen from the previous average price target of $107.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1737486053_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Best Buy Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Steven Forbes</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$95.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$101.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Best Buy Co. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Best Buy Co compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Best Buy Co's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BBY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Best Buy Co analyst ratings.</a>
<h2>About Best Buy Co</h2>
With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
<h3>Best Buy Co: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Best Buy Co's revenue growth over a period of 3 months has faced challenges. As of 31 October, 2024, the company experienced a revenue decline of approximately -3.19%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.89%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Best Buy Co's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.82% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Best Buy Co's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.67% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Best Buy Co's debt-to-equity ratio surpasses industry norms, standing at 1.32. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 12 Analyst Ratings Have To Say About Best Buy Co

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $271.1, a high estimate of $323.00, and a low estimate of $235.00. Surpassing the previous average price target of $230.75, the current average has increased by 17.49%.
<img src="https://www.benzinga.com/files/images/story/2025/1737486036_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Penumbra by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priya Sachdeva</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$285.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Steve Lichtman</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$275.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$323.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$248.00</td>
<td>$244.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Penumbra. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Penumbra compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Penumbra's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Penumbra's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PEN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Penumbra analyst ratings.</a>
<h2>About Penumbra</h2>
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
<h3>Penumbra: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Penumbra's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.11% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Penumbra's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 9.81%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Penumbra's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.61%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.96%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.21.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Assess Penumbra: What You Need To Know

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 11/25/2024, According to Top Analysts

indie Semiconductor (INDI) has launched a system basis safety integrated chip or IC solution for vehicle powertrain applications…The solution has b...

Indie debuts system basis safety IC solution for vehicle powertrain applications

indie Semiconductor shares fall on convertible senior notes offering

indie Semiconductor (INDI) announced that it plans to offer, subject to market and other conditions, $175M aggregate principal amount of its conver...

Indie Semiconductor announces $175M convertible senior notes offering

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – Credo Technology (CRDO)&nbsp;...

Closing Bell Movers: Zscaler down 8% despite earnings beat

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: The Delaware Court of Chancery y...

AT&T announces long-term targets, BlackRock acquires HPS: Morning Buzz

indie semiconductor prices note offering

There's a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Ingram Micro Holding Corporation (INGM – Research Re...

Analysts Offer Insights on Technology Companies: Ingram Micro Holding Corporation (INGM), indie Semiconductor (INDI) and Coherent Corp (COHR)

There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Guidewire (GWRE – Research Report) and indie Semicon...

Analysts Are Bullish on Top Technology Stocks: Guidewire (GWRE), indie Semiconductor (INDI)

Despite a challenging 2024, indie Semiconductor($INDI) anticipates substantial growth in 2025 and beyond, mainly due to the rising demand for elect...

indie Semiconductor's $7.1 Billion Backlog Promises Strong Growth Potential for 2025

AMZN

BBAI

BYDDF

BYDDY

CART

COHR

CRDO

GWRE

INDI

INGM

INTC

JANX

MCHP

NISTF

NPSCY

NVDA

PLTR

PRCH

RCAT

STLA

TMDX

TSLA

UPST

Press Releases

indie Semiconductor Extends In-cabin User Experience Portfolio With Addition of Qi2 MPP-compliant Wireless Charging Solution

indie Semiconductor Announces New Employee Inducement Grants

indie Semiconductor Sets Date for Third Quarter 2024 Earnings Release and Conference Call

indie Semiconductor's Latest Vision Processor Design-win Momentum Accelerates, Awarded Sensor Innovation of the Year

indie Semiconductor to Participate at Upcoming Investor Events

indie Semiconductor Exceeds Third Quarter 2024 Growth Expectations, Guides Accelerating Fourth Quarter

indie Semiconductor Extends Automotive Photonics Leadership With Advanced Optical Component Integration Capabilities

indie Announces Automotive System Basis Safety IC Solution With Leading European Tier 1, Independently Certified To The Highest Functional Safety Rating

indie Semiconductor Announces Proposed Convertible Senior Notes Offering

indie Semiconductor Announces Pricing of Private Offering

Ambarella

Alpha and Omega Semiconductor Limited - Common Shares

Alpha & Omega

CEVA

Canadian Solar

Diodes

Himax Technologies, Inc. - American depositary shares, each of which represents two ordinary shares.

Himax Techs

Intchains Group Limited - American Depositary Shares

Intchains Gr

ChipMOS TECHNOLOGIES INC. - American Depositary Shares

ChipMOS TECHNOLOGIES

JinkoSolar Holding Company Limited American Depositary Shares (each representing 4 Common Shares)

JinkoSolar Holding Co

Kopin

SEALSQ

Everspin Technologies, Inc. - Common Stock

Everspin Technologies

Magnachip Semiconductor Corporation Common Stock

MagnaChip Semiconductor

MaxLinear

Navitas Semiconductor Corporation - Common Stock

Navitas Semiconductor

Penguin Solutions, Inc. - Ordinary Shares

Penguin Solutions

Rigetti Computing

Silicon Motion Technology Corporation - American Depositary Shares, each representing four ordinary shares

Silicon Motion Technology

SkyWater Technology

Sequans Communications S.A. American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

Indie Semiconductor

Indie Semiconductor (INDI) Opzioni

Indie Semiconductor (NASDAQ:INDI) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO